XBRL Proof

XBRL File

Document - Document and Entity Information

Document - Document and Entity Information (USD $)	3 Months Ended
( custom:DocumentAndEntityInformationAbstract [Extension] )
	Mar. 31, 2016	May. 16, 2016



Entity Registrant Name	Artventive Medical Group, Inc.
( dei:EntityRegistrantName )
Entity Central Index Key	0001405249
( dei:EntityCentralIndexKey )
Document Type	10-Q
( dei:DocumentType )
Document Period End Date	2016-03-31
( dei:DocumentPeriodEndDate )
Amendment Flag	false
( dei:AmendmentFlag )
Current Fiscal Year End Date	--12-31
( dei:CurrentFiscalYearEndDate )
Is Entity a Well-known Seasoned Issuer?	No
( dei:EntityWellKnownSeasonedIssuer )
Is Entity a Voluntary Filer?	No
( dei:EntityVoluntaryFilers )
Is Entity's Reporting Status Current?	Yes
( dei:EntityCurrentReportingStatus )
Entity Filer Category	Smaller Reporting Company
( dei:EntityFilerCategory )
Entity Public Float
( dei:EntityPublicFloat )
Entity Common Stock, Shares Outstanding		63,637,086
( dei:EntityCommonStockSharesOutstanding )
Document Fiscal Period Focus	Q1
( dei:DocumentFiscalPeriodFocus )
Document Fiscal Year Focus	2016
( dei:DocumentFiscalYearFocus )

(End Document - Document and Entity Information)

Statement - Balance Sheets (Unaudited)

Statement - Balance Sheets (Unaudited) (USD $)
( us-gaap:StatementOfFinancialPositionAbstract )
	Mar. 31, 2016		Dec. 31, 2015





ASSETS
( us-gaap:AssetsAbstract )


Current assets
( us-gaap:AssetsCurrentAbstract )
Cash and cash equivalents	10,106		21,781
( us-gaap:CashAndCashEquivalentsAtCarryingValue )
Accounts receivable	24,976		18,118
( us-gaap:AccountsReceivableNet )
Prepaid expenses	6,166		11,655
( us-gaap:PrepaidExpenseCurrent )
Inventory	311,411		303,044
( us-gaap:InventoryGross )


Total current assets	352,659		354,598
( us-gaap:AssetsCurrent )


Fixed assets
( us-gaap:AssetsNoncurrentAbstract )
Office equipment	26,870		26,870
( us-gaap:PropertyPlantAndEquipmentOther )
Accumulated depreciation	(10,809	)	(9,582	)
( us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment )


Fixed assets, net	16,061		17,288
( us-gaap:AssetsNet )


Other assets
( us-gaap:OtherAssetsAbstract )
Deposits	77,391		81,530
( us-gaap:Deposits )


Total other assets	77,391		81,530
( us-gaap:OtherAssets )


Total assets	446,111		453,416
( us-gaap:Assets )


LIABILITIES AND STOCKHOLDERS' DEFICIT
( us-gaap:LiabilitiesAndStockholdersEquityAbstract )


Current liabilities
( us-gaap:LiabilitiesCurrentAbstract )
Accounts payable	1,444,825		924,089
( us-gaap:AccountsPayableCurrent )


Total current liabilities	1,444,825		924,089
( us-gaap:LiabilitiesCurrent )


Long-term liabilities
( us-gaap:LongTermDebtAbstract )
Notes payable	500,000		500,000
( us-gaap:NotesPayable )


Total long-term liabilities	500,000		500,000
( us-gaap:LongTermDebtNoncurrent )


Total liabilities	1,944,825		1,424,089
( us-gaap:AccruedLiabilitiesCurrentAndNoncurrent )




Stockholders' deficit
( us-gaap:StockholdersEquityAbstract )
Common stock, $0.001 par value, 100,000,000 shares authorized, 63,687,086 and 63,592,086 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	63,687		63,592
( us-gaap:CommonStockParOrStatedValuePerShare )
Additional paid in capital	17,043,485		17,028,580
( us-gaap:AdditionalPaidInCapital )
Accumulated deficit	(18,605,886	)	(18,062,845	)
( us-gaap:CumulativeEarningsDeficit )


Total stockholders' deficit	(1,498,714	)	(970,673	)
( us-gaap:StockholdersEquity )


Total liabilities and stockholders' deficit	446,111		453,416
( us-gaap:LiabilitiesAndStockholdersEquity )

(End Statement - Balance Sheets (Unaudited))

Statement - Balance Sheets (Parenthetical)

Statement - Balance Sheets (Parenthetical) (USD $)
( us-gaap:StatementOfFinancialPositionAbstract )
	Mar. 31, 2016	Dec. 31, 2015



Common Stock, $.001 par value, shares authorized	100,000,000	100,000,000
( us-gaap:CommonStockSharesAuthorized )
Common Stock, $.001 par value, shares issued and outstanding	63,687,086	63,592,086
( us-gaap:CommonStockSharesIssued )

(End Statement - Balance Sheets (Parenthetical))

Statement - Statements of Operations (Unaudited)

Statement - Statements of Operations (Unaudited) (USD $)	3 Months Ended
( us-gaap:IncomeStatementAbstract )
	Mar. 31, 2016		Mar. 31, 2015





REVENUES	45,986		64,187
( us-gaap:Revenues )
COST OF SALES	45,986		64,187
( us-gaap:CostOfGoodsSold )
GROSS PROFIT	�		�
( us-gaap:GrossProfit )


OPERATING EXPENSES
( us-gaap:OperatingExpensesAbstract )
Research and development	179,653		301,926
( us-gaap:ResearchAndDevelopmentExpense )
Selling, general and administrative	362,161		585,327
( us-gaap:SellingGeneralAndAdministrativeExpense )
Depreciation expense	1,227		930
( us-gaap:Depreciation )
Total operating expenses	543,041		888,183
( us-gaap:OperatingExpenses )


Loss from operations	(543,041	)	(888,183	)
( us-gaap:IncomeLossFromContinuingOperations )


OTHER INCOME (EXPENSE)
( us-gaap:OtherIncomeAndExpensesAbstract )
Interest expense	�		�
( us-gaap:InterestExpense )
Interest income	�		1
( us-gaap:InterestAndDividendIncomeOperating )
Total other income (expense)	�		1
( us-gaap:OtherNonoperatingIncomeExpense )


NET LOSS	(543,041	)	(888,182	)
( us-gaap:NetIncomeLoss )


LOSS PER SHARE - Basic and Diluted	(0.01	)	(0.01	)
( us-gaap:EarningsPerShareBasicAndDiluted )


WEIGHTED AVERAGE SHARES OUTSTANDING	63,643,586		59,765,175
( us-gaap:WeightedAverageBasicSharesOutstandingProForma )

(End Statement - Statements of Operations (Unaudited))

Statement - Statements of Cash Flows (Unaudited)

Statement - Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
( us-gaap:StatementOfCashFlowsAbstract )
	Mar. 31, 2016		Mar. 31, 2015





CASH FLOWS FROM OPERATING ACTIVITIES:
( us-gaap:NetCashProvidedByUsedInOperatingActivitiesAbstract )
Net loss	(543,041	)	(888,182	)
( us-gaap:NetIncomeLoss )
Adjustments to reconcile net loss to net cash used in operating activities
( us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract )
Non-cash expenses	�		33,715
( us-gaap:OtherNoncashExpense )
Depreciation expense	1,227		930
( us-gaap:DepreciationAndAmortization )
Changes in operating assets and liabilities:
( us-gaap:IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract )
Accounts receivable	(6,858	)	52
( us-gaap:IncreaseDecreaseInAccountsReceivable )
Prepaid expenses	5,489		�
( us-gaap:IncreaseDecreaseInPrepaidExpense )
Inventory	(8,367	)	(37,949	)
( us-gaap:IncreaseDecreaseInInventories )
Deposits	4,139		(3,862	)
( us-gaap:IncreaseDecreaseInDeposits )
Accounts payable	520,736		262,125
( us-gaap:IncreaseDecreaseInAccountsPayable )
Payroll taxes payable	�		61
( us-gaap:OtherLaborRelatedExpenses )
Accrued expenses	�		(37,500	)
( us-gaap:IncreaseDecreaseInAccruedLiabilities )
Cash used in operating activities	(26,675	)	(670,610	)
( us-gaap:NetCashProvidedByUsedInOperatingActivities )


CASH FLOWS FROM INVESTING ACTIVITIES:
( us-gaap:NetCashProvidedByUsedInInvestingActivitiesAbstract )
Cash paid for purchase of fixed assets	�		(2,940	)
( us-gaap:PaymentsForPurchaseOfOtherAssets1 )
Cash used in investing activities	�		(2,940	)
( us-gaap:NetCashProvidedByUsedInInvestingActivities )


CASH FLOWS FROM FINANCING ACTIVITIES:
( us-gaap:NetCashProvidedByUsedInFinancingActivitiesAbstract )
Proceeds from sale of common stock	15,000		650,000
( us-gaap:ProceedsFromIssuanceOrSaleOfEquity )
Issuance of notes payable	�		�
( us-gaap:ProceedsFromNotesPayable )
Cash provided by financing activities	15,000		650,000
( us-gaap:NetCashProvidedByUsedInFinancingActivities )


NET CHANGE IN CASH	(11,675	)	(23,550	)
( us-gaap:CashPeriodIncreaseDecrease )
CASH AT BEGINNING OF PERIOD	21,781		104,030
( us-gaap:Cash )
CASH AT END OF PERIOD	10,106		80,480
( us-gaap:Cash )


CASH PAID DURING THE YEAR:
( us-gaap:SupplementalCashFlowInformationAbstract )
Interest paid	�		�
( us-gaap:InterestPaid )
Income taxes paid	�		�
( us-gaap:IncomeTaxesPaidNet )


NON-CASH TRANSACTIONS:
( us-gaap:NoncashOrPartNoncashAcquisitionNameDomain )
Accrual of Stock Issuance Cost	�		65,000
( us-gaap:PaymentsOfStockIssuanceCosts )

(End Statement - Statements of Cash Flows (Unaudited))

Disclosure - Base of Financial Statement Presentation

Disclosure - Base of Financial Statement Presentation (USD $)	3 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Mar. 31, 2016



Basis of Financial Statement Presentation	NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared by ArtVentive Medical Group, Inc. and its Subsidiary, ArtVentive Medical Group, Canada Inc., (the “Company”) pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and should be read in conjunction with our annual report on Form 10-K for the year ended December 31, 2015 as filed with the SEC under the Securities and Exchange Act of 1934 (the“Exchange Act”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, as permitted by the SEC, although we believe the disclosures which are made are adequate to make the information presented not misleading. The condensed consolidated financial statements reflect, in the opinion of management, all normal recurring adjustments necessary to present fairly our financial position at March 31, 2016 and the results of our operations and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year, or any other period.
( us-gaap:BasisOfAccounting )

(End Disclosure - Base of Financial Statement Presentation)

Disclosure - Organization

Disclosure - Organization (USD $)	3 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Mar. 31, 2016



Organization	NOTE 2 - ORGANIZATION The Company is a medical device company focused on developing, manufacturing and marketing a family of endoluminal occlusion devices, known as the Endoluminal Occlusion System (EOS™). Through its patented technology, the Company has developed minimally invasive occlusion devices and procedures capable of achieving immediate, complete, and permanent occlusion of peripheral vasculature. EOS™ was developed by the Company and serves as a proprietary technology platform for several major clinical areas including peripheral and neurological vascular disorders, women's health, interventional oncology and cardiology procedures. The Company was incorporated on January 23, 2007. The Company’s fiscal year end is December 31. To date, the Company’s activities have been committed to the development of EOS™, intellectual property, animal studies, human studies, patent filings, and developing a regulatory strategy for initial clinical indications pertinent to European, manufacturing and FDA submissions and approvals, corporate operations and the raising of equity capital. The Company conducted the required human clinical studies during 2011, achieving 100% clinical and procedural success, validating the safety and efficiency of the EOS^TM device. The Company received its CE Mark certification for EOS™ on May 30, 2013. In 2014, the Company began commercialization and commenced marketing with its European distributors. On December 3, 2014, the Company received FDA approval for EOS™ for marketing and sales in the United States. We currently have one wholly-owned subsidiary, ArtVentive Medical Group, Canada Inc.
( us-gaap:NatureOfOperations )

(End Disclosure - Organization)

Disclosure - Significant Accounting Policies

Disclosure - Significant Accounting Policies (USD $)

3 Months Ended

( AccountingPoliciesAbstract )

Mar. 31, 2016

Significant Accounting Policies

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The consolidated financial statements include the transactions of the Company and its Subsidiary. All inter-company accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the Company’s financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Such estimates include deferred tax assets arising as a result of the operating loss carry forwards. Actual results could differ from those estimates. The Company’s periodic filings with the SEC include, where applicable, disclosures of estimates, assumptions, uncertainties and markets that could affect the financial statements and future operations of the Company.

Common Stock Issued for Services

Services purchased and other transactions settled in the Company’s common stock and stock options are recorded at the estimated fair value of the stock issued and options granted if that value is more readily determinable than the fair value of the consideration received.

Earnings Per Share of Common Stock

In accordance with accounting guidance now codified as FASB ASC Topic 260, Earnings per Share, basic earnings (loss) per share is computed by dividing net income (loss) by weighted average number of shares of common stock outstanding during each period.

Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period.

The Company had the following potential common stock equivalents at March 31, 2016:

Common stock warrants		2,415,000
Common stock options		370,000
Total common stock equivalents		2,785,000

Since the Company recorded net losses for the three months ended March 31, 2016 and 2015, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. Therefore, a separate computation of diluted earnings (loss) per share is not presented.

The following table sets forth the computation of earnings per share:

	March 31, 2016		March 31, 2015
Net income (loss)	$	(543,041)	$	(888,182)
Weighted average common shares outstanding		63,643,586		59,765,175
Net (loss) per share	$	(0.01)	$	(0.01)

Property and Equipment

The Company records property and equipment at cost and uses straight-line depreciation methods over estimated useful lives of 5-7 years.

	March 31, 2016		December 31, 2015
Computer equipment	$	22,124	$	22,124
Office furniture		4,746		4,746
Less: Accumulated depreciation		(10,809)		(9,582)
Net property and equipment	$	16,061	$	17,288

Inventory

The Company’s inventory is valued at the lower of cost or market using the first-in, first-out (FIFO) method. As of March 31, 2016 and December 31, 2015, all inventory consisted of finished goods.

As the Company begins its transition from the research and development phase to production, management has estimated the cost of units sold to be equal to the revenue generated on those units. Other direct cost that may be associated with the production of these units has been reflected in research and development expenses.

Foreign Currency Translations

The Company’s functional and reporting currency is the U.S. dollar. All transactions initiated in other currencies are translated into U.S. dollars using the exchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated into the U.S. dollar at the rate of exchange in effect at the balance sheet date. Unrealized exchange gains and losses arising from such transactions are deferred until realization and are included as a separate component of stockholders’ equity (deficit) as a component of other comprehensive income or loss. Upon realization, the amount deferred is recognized in income in the period when it is realized.

Cash and Cash Equivalents

Cash and cash equivalents consist principally of funds on hand, on deposit with banks and liquid investment funds having maturity of three months or less at the time of the purchase. The Company has no cash equivalents. The Company had funds on deposit of $10,106 as of March 31, 2016.

Receivables

The accounts receivable balance of $24,976 as of March 31, 2016 is comprised of balances due from six customers totaling $8,311, $4,800, $3,280, $2,915, $2,850 and $2,790. The accounts receivable balance as of December 31, 2015 was comprised of balances due from four customers totaling $5,760, $5,568, $3,210, and $3,580. The balance of the allowance for bad debts was $0 as of March 31, 2016 and December 31, 2015.

Revenue Recognition

Revenue for the sale of goods in the course of the ordinary activities is measured at the fair value of the consideration received or receivable, net of returns. Revenue for sale of goods is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of the goods can be estimated reliably, there is no continuing involvement with the goods, and the amount of revenue can be measured reliably.

Concentrations of Credit Risk

Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and accounts receivable. The Company maintains cash balances at financial institutions, which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits of $250,000. As of March 31, 2016, the Company had no deposits in excess of federally insured limits in its U.S. bank. The Company has not experienced any losses with regard to its bank accounts and believes it is not exposed to any risk of loss on its cash in bank accounts. As of March 31, 2016, six customers represented 100% (33.3%, 19.25%, 13.15%, 11.69%, 11.43% and 11.19%) and as of December 31, 2015, four customers represented 100% (31.8%, 30.7%, 17.7% and 19.8%) of our accounts receivable.

As of March 31, 2016 and December 31, 2015, Medical Murray, accounted for more than 10% of our purchases and accounts payable.

( us-gaap:SignificantAccountingPoliciesTextBlock )

(End Disclosure - Significant Accounting Policies)

Disclosure - Notes Payable

Disclosure - Notes Payable (USD $)

3 Months Ended

( DebtDisclosureAbstract )

Mar. 31, 2016

Notes Payable

NOTE 4 – NOTES PAYABLE

On April 1, 2014, the Company borrowed $250,000 from an unrelated party and issued a note payable due on or before December 31, 2014, with interest at 3% per annum. On December 31, 2014, the Company and the lender executed an extension of the note, which is due on or before December 31, 2017. The interest remains at 3%. The lender may convert all or part of the debt, including interest, into common stock of the Company at any time at the rate of $1.00 per share.

On April 1, 2014, the Company borrowed an additional $250,000 from an unrelated party and issued a note payable due on or before December 31, 2014, with interest at 3% per annum. On December 31, 2014, the Company and the lender executed an extension of the note, which is due on or before December 31, 2017. The interest remains at 3%. The lender may convert all or part of the debt, including interest, into common stock of the Company at any time at the rate of $1.00 per share.

Long-term debt consists of the following:

	March 31, 2016		December 31, 2015

Note payable to a private party, interest at 3.0%, interest and principal due December 31, 2017	$	250,000	$	250,000
Note payable to a private party, interest at 3.0%, interest and principal due December 31, 2017		250,000		250,000
		500,000		500,000
Less current maturities of long-term debt		-		-
Long-term debt	$	500,000	$	500,000

Maturities on long-term debt are as follows:

2016	$	-
2017		500,000
	$	500,000

( us-gaap:DebtDisclosureTextBlock )

(End Disclosure - Notes Payable)

Disclosure - Stockholers Equity

Disclosure - Stockholers Equity (USD $)

3 Months Ended

( EquityAbstract )

Mar. 31, 2016

Stockholders Equity

NOTE 5 - STOCKHOLDERS’ EQUITY

Effective April 22, 2008, the Company forward-split its issued common stock on a ratio of 5.8 shares for each original share. As a result of this transaction, 11,078,000 shares were issued. Effective February 12, 2010, the Company forward-split its issued common stock on a ratio of 1.65 shares for each one prior share. As a result of this transaction, 8,442,200 shares were issued. Consideration for the issue of additional shares has been charged against additional paid in capital. The forward stock splits adjustments have been applied retroactively.

Stock issuances in private placements during the three months ended March 31, 2016 and the years ended December 31, 2015 and December 31, 2014 are as follows:

Stock Issuance Date	Common Shares		Proceeds Received

January 7, 2014	400,000	$	400,000
February 11, 2014	400,000		400,000
March 6, 2014	300,000		300,000
May 23, 2014	100,000		100,000
June 24, 2014	1,000,000		1,000,000
July 23, 2014	500,000		500,000
August 29, 2014	250,000		250,000
September 29, 2014	150,000		150,000
September 30, 2014	100,000		100,000
October 15, 2014	100,000		100,000
November 7, 2014	80,000		80,000
November 28, 2014	70,000		70,000
December 4, 2014	250,000		250,000
December 15, 2014	250,000		250,000
December 29, 2014	250,000		250,000

Total for year ended December 31, 2014	4,200,000	$	4,200,000

January 23, 2015	250,000	$	250,000
February 27, 2015	150,000		150,000
March 15, 2015	100,000		100,000
March 31, 2015	150,000		150,000
April 23, 2015	150,000		150,000
May 4, 2015	100,000		100,000
May 29, 2015	500,000		500,000
June 1 2015	500,000		500,000
July 17, 2015	200,000		200,000
August 8, 2015	50,000		50,000
August 27, 2015	300,000		300,000
September 28, 2015	250,000		250,000
October 26, 2015	150,000		150,000
November 20, 2015	100,000		100,000
December 12, 2015	100,000		100,000

Total for year ended December 31, 2015	3,050,000	$	3,050,000

January 18, 2016	15,000	$	15,000

Total for three months ended March 31, 2016	15,000	$	15,000

On May 5, 2015, 980,800 shares were issued for finder’s fees valued at $980,800.

On August 12, 2015, 25,000 shares were issued for finder’s fees valued at $25,000.

On January 22, 2016, 80,000 shares were issued for finder’s fees valued at $80,000.

( us-gaap:StockholdersEquityNoteDisclosureTextBlock )

(End Disclosure - Stockholers Equity)

Disclosure - Going Concern and Liquidity Considerations

Disclosure - Going Concern and Liquidity Considerations (USD $)	3 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Mar. 31, 2016



Going Concern and Liquidity Considerations	NOTE 6 - GOING CONCERN AND LIQUIDITY CONSIDERATIONS The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of March 31, 2016, the Company had a negative working capital balance of $1,092,166 and an accumulated deficit of $18,605,886. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management is in the process of evaluating various financing alternatives for operations, as the Company will need to finance future research and development activities and general and administrative expenses through fund raising in the public or private equity markets. Management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders. However, there is no assurance that the Company will be successful with those initiatives, and it does not have any firm commitments from investors at this time.
( us-gaap:LiquidityDisclosureTextBlock )

(End Disclosure - Going Concern and Liquidity Considerations)

Disclosure - Recently Issued Accounting Pronouncements

Disclosure - Recently Issued Accounting Pronouncements (USD $)	3 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Mar. 31, 2016



Recently Issued Accounting Pronouncements	NOTE 7 - recently issued accounting pronouncements The Company has reviewed Accounting Standards Update (“ASU”) through ASU No. 2016-11 which contain technical corrections to existing guidance or affect guidance to specialized industries or entities. These updates have no current applicability to the Company or their effect on the financial statements would not have been significant.
( us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock )

(End Disclosure - Recently Issued Accounting Pronouncements)

Disclosure - Provision for Income Taxes

Disclosure - Provision for Income Taxes (USD $)

3 Months Ended

( IncomeTaxDisclosureAbstract )

Mar. 31, 2016

Provision for Income Taxes

note 8 - provision for income taxes

The Company recognizes the tax effects of transactions in the year in which such transactions enter into the determination of net income, regardless of when reported for tax purposes. Deferred taxes are provided in the financial statements under ASC Topic 740, Income Taxes, to give effect to the resulting temporary differences which may arise from differences in the bases of fixed assets, depreciation methods, allowances, and start-up costs based on the income taxes expected to be payable in future years. Exploration and development stage deferred tax assets arising as a result of net operating loss carry forwards have been offset completely by a valuation allowance due to the uncertainty of their utilization in future periods. Tax operating loss carry forwards generated during the period from January 23, 2007 (date of inception) through March 31, 2016 of approximately $18.4 million will begin to expire in 2027. Accordingly, deferred tax assets of approximately $7,731,000 (2015 – $7,594,000) related to net operating loss carryforwards and $168,000 related to stock-based compensation were offset in full by the valuation allowance.

The Company has no tax positions at March 31, 2016 and December 31, 2015 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility.

The Company’s tax returns for the years ended December 31, 2015, 2014, 2013 and 2012 are open for examination under Federal Statute of Limitations and for the years ended December 31, 2015, 2014 and 2013 under the State of California Statute of Limitations.

The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company had no accruals for interest and penalties since inception.

A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax to income before provision for income taxes is as follows:

		For the Three Months Ended March 31,
		2016		2015
Income tax (benefit) computed at
Federal statutory tax rate of 34%	$	(184,634)	$	(290,518)
Change in valuation allowance		232,639		366,053
State taxes (net of federal benefit)		(48,005)		(75,535)
	$	-	$	-

( us-gaap:IncomeTaxDisclosureTextBlock )

(End Disclosure - Provision for Income Taxes)

Disclosure - Warrants and Options

Disclosure - Warrants and Options (USD $)

3 Months Ended

( OtherLiabilitiesDisclosureAbstract )

Mar. 31, 2016

Warrants and Options

NOTE 9 - WARRANTS AND OPTIONS

During the year ended December 31, 2015, the Company granted 3,050,000 warrants to purchase shares of Common Stock of which all have a 1-year exercise term, of which 2,400,000 remain outstanding at March 31, 2016. During the quarter ended March 31, 2016, 15,000 warrants were issued. The Company valued all warrants utilizing a Black-Scholes option-pricing model and the fair value was recorded as additional paid-in capital.

The following is a summary of the Company’s warrant activity as of March 31, 2016:

	Warrants		Weighted Average Exercise Price

Outstanding - December 31, 2014	4,200,000	$	1.50
Granted	3,050,000		1.50
Exercised	-		-
Forfeited	(4,200,000)		1.50
Outstanding – December 31, 2015	3,050,000	$	1.50
Exercisable – December 31, 2015	3,050,000	$	1.50

Granted	15,000	$	1.50
Exercised	-		-
Forfeited	(650,000)	$	1.50
Outstanding – March 31, 2016	2,415,000	$	1.50
Exercisable – March 31, 2016	2,415,000	$	1.50

Warrants outstanding and exercisable at March 31, 2016 are as follows:

Warrants Outstanding				Warrants Exercisable
	Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life (in Years)	Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	1.50	50,000	0.04 years	$	1.50		50,000		$	1.50
$	1.50	150,000	0.06 years	$	1.50		150,000		$	1.50
$	1.50	100,000	0.09 years	$	1.50		100,000		$	1.50
$	1.50	500,000	0.15 years	$	1.50		500,000		$	1.50
$	1.50	500,000	0.17 years	$	1.50		500,000		$	1.50
$	1.50	200,000	0.29 years	$	1.50		200,000		$	1.50
$	1.50	300,000	0.41 years	$	1.50		300,000		$	1.50
$	1.50	250,000	0.49 years	$	1.50		250,000		$	1.50
$	1.50	150,000	0.57 years	$	1.50		150,000		$	1.50
$	1.50	100,000	0.64 years	$	1.50		100,000		$	1.50
$	1.50	100,000	0.70 years	$	1.50		100,000		$	1.50
$	1.50	15,000	0.80 years	$	1.50		15,000		$	1.50

Warrant activity is as follows:

Warrants issued during the first quarter of 2016, totaled 15,000.

Warrants issued during 2015, totaling 650,000, expired during the first quarter of 2016.

Warrants issued during 2014, totaling 4,200,000, expired during 2015.

Effective April 16, 2015, 50,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective April 23, 2015, 150,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective May 4, 2015, 100,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective May 28, 2015, 500,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective June 1, 2015, 500,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective July 17, 2015, 200,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective August 12, 2015, 25,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective August 27, 2015, 300,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective September 28, 2015, 250,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective October 26, 2015, 150,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective November 20, 2015, 100,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective December 12, 2015, 100,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

Effective January 18, 2016, 15,000 warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants expire in 1 year.

The following is a summary of the Company’s stock options activity:

	Options		Weighted Average Exercise Price
Granted – 2015	265,000	$	1.00
Exercised – 2015	(50,000)		0.001
Forfeited – 2015	(150,000)		1.00
Outstanding – December 31, 2015	370,000	$	1.00
Exercisable – December 31, 2015	230,000	$	1.00

Granted	-	$	-
Exercised	-		-
Forfeited	-		-
Outstanding – March 31, 2016	370,000	$	1.00
Exercisable – March 31, 2016	230,000	$	1.00

Options outstanding and exercisable at March 31, 2016 are as follows:

Options Outstanding							Options Exercisable
	Range of Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life (in Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$		1.00		35,000		1.84 years	$	1.00		35,000		$	1.00
$		1.00		10,000		1.92 years	$	1.00		10,000		$	1.00
$		1.00		10,000		2.74 years	$	1.00		10,000		$	1.00
$		1.00		50,000		7.67 years	$	1.00		50,000		$	1.00
$		1.00		10,000		8.81 years	$	1.00		10,000		$	1.00
$		1.00		100,000		9.08 years	$	1.00		100,000		$	1.00
$		1.00		40,000		9.21 years	$	1.00		-		$	1.00
$		1.00		15,000		9.41 years	$	1.00		15,000		$	1.00
$		1.00		100,000		9.48 years	$	1.00		-		$	1.00

The Company’s stock option activity is as follows:

Effective November 2, 2010, the Board of Directors of the Company granted 50,000 non-statutory stock options to a current consultant at an exercise price of $.001 per share with the vesting date of November 2, 2013 and an expiration date of November 2, 2016. These options were exercised on August 7, 2015.

Effective February 1, 2013, the Board of Directors of the Company granted 20,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of February 1, 2013 and an expiration date of February 1, 2018.

Effective February 1, 2013, the Board of Directors of the Company granted 5,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of February 1, 2013 and an expiration date of February 1, 2018.

Effective February 1, 2013, the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of February 1, 2013 and an expiration date of February 1, 2018.

Effective March 1, 2013, the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of March 1, 2013 and an expiration date of March 1, 2018.

Effective December 27, 2013, the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of December 27, 2013, and an expiration date of December 27, 2018.

Effective January 1, 2015, the Board of Directors of the Company granted 200,000 non-statutory stock options to a then current employee at an exercise price of $1.00 per share with 50,000 of the shares vested on January 1, 2016 and the additional 75% of the shares exercisable on each of the next succeeding three anniversaries of January 1. The 50,000 vested stock options remain outstanding, while the 150,000 non-vested options were forfeited through a voluntary resignation on September 4, 2015.

Effective January 23, 2015, the Board of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of January 23, 2015, and an expiration date of January 23, 2025.

Effective April 30, 2015, the Board of Directors of the Company granted 100,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of April 30, 2015, and an expiration date of April 30, 2025.

Effective June 15, 2015, the Board of Directors of the Company granted 40,000 non-statutory stock options to a current employee at an exercise price of $1.00 per share with 25% of the shares exercisable on June 15, 2016 and an additional 25% exercisable on each of the next succeeding three anniversaries of June 15, on a cumulative basis, so that the option, or any unexercised portion, shall be fully exercisable on and after June 15, 2019. The stock options have an expiration date of June 15, 2025.

Effective August 28, 2015, the Board of Directors of the Company granted 15,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the vesting date of August 28, 2015, and an expiration date of August 28, 2025.

Effective September 22, 2015, the Board of Directors granted 100,000 stock options deemed an Incentive Stock Option (ISO) to a current employee, at an exercise price of $1.00 per share with 25% exercisable on September 22, 2016; and an additional 25% exercisable on each of the next succeeding three anniversaries of September 22nd, on a cumulative basis, so that the Option, or any unexercised portion, shall be fully exercisable on and after September 22, 2019. The stock options have an expiration date of September 22, 2025.

The Company valued these options utilizing a Black-Scholes option-pricing model and the fair value was recorded as additional paid-in capital.

( us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock )

(End Disclosure - Warrants and Options)

Disclosure - Subsequent Events

Disclosure - Subsequent Events (USD $)	3 Months Ended
( SubsequentEventsAbstract )
	Mar. 31, 2016



Subsequent Events	NOTE 10 - subsequent events The Company evaluated all events or transactions that occurred after March 31, 2016, up through the date these unaudited condensed consolidated financial statements were issued and it was determined there were no reportable events.
( us-gaap:SubsequentEventsTextBlock )

(End Disclosure - Subsequent Events)

Disclosure - Significant Accounting Policies (Policies)

Disclosure - Significant Accounting Policies (Policies) (USD $)

3 Months Ended

( AccountingPoliciesAbstract )

Mar. 31, 2016

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the transactions of the Company and its Subsidiary. All inter-company accounts and transactions have been eliminated in consolidation.

( us-gaap:ConsolidationPolicyTextBlock )

Use of Estimates

Use of Estimates

( us-gaap:UseOfEstimates )

Common Stock Issued for Services

Common Stock Issued for Services

( us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock )

Earnings Per Share of Common Stock

Earnings Per Share of Common Stock

The Company had the following potential common stock equivalents at March 31, 2016:

Common stock warrants		2,415,000
Common stock options		370,000
Total common stock equivalents		2,785,000

The following table sets forth the computation of earnings per share:

	March 31, 2016		March 31, 2015
Net income (loss)	$	(543,041)	$	(888,182)
Weighted average common shares outstanding		63,643,586		59,765,175
Net (loss) per share	$	(0.01)	$	(0.01)

( us-gaap:EarningsPerSharePolicyTextBlock )

Property and Equipment

Property and Equipment

The Company records property and equipment at cost and uses straight-line depreciation methods over estimated useful lives of 5-7 years.

	March 31, 2016		December 31, 2015
Computer equipment	$	22,124	$	22,124
Office furniture		4,746		4,746
Less: Accumulated depreciation		(10,809)		(9,582)
Net property and equipment	$	16,061	$	17,288

( us-gaap:PropertyPlantAndEquipmentPolicyTextBlock )

Inventory

Inventory

The Company’s inventory is valued at the lower of cost or market using the first-in, first-out (FIFO) method. As of March 31, 2016 and December 31, 2015, all inventory consisted of finished goods.

( us-gaap:InventoryPolicyTextBlock )

Foreign Currency Translations

Foreign Currency Translations

( us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock )

Cash and Cash Equivalents

Cash and Cash Equivalents

( us-gaap:CashAndCashEquivalentsPolicyTextBlock )

Receivables

Receivables

( us-gaap:ReceivablesPolicyTextBlock )

Revenue Recognition

Revenue Recognition

( us-gaap:RevenueRecognitionPolicyTextBlock )

Concentrations of Credit Risk

Concentrations of Credit Risk

As of March 31, 2016 and December 31, 2015, Medical Murray, accounted for more than 10% of our purchases and accounts payable.

( us-gaap:ConcentrationRiskCreditRisk )

(End Disclosure - Significant Accounting Policies (Policies))

Disclosure - Significant Accounting Policies (Tables)

Disclosure - Significant Accounting Policies (Tables) (USD $)

3 Months Ended

( AccountingPoliciesAbstract )

Mar. 31, 2016

Common Stock Equivalents

Common stock warrants		2,415,000
Common stock options		370,000
Total common stock equivalents		2,785,000

( us-gaap:ScheduleOfDerivativeInstrumentsTextBlock )

Computations of Earnings Per Share

	March 31, 2016		March 31, 2015
Net income (loss)	$	(543,041)	$	(888,182)
Weighted average common shares outstanding		63,643,586		59,765,175
Net (loss) per share	$	(0.01)	$	(0.01)

( us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock )

Equipment Depreciation

	March 31, 2016		December 31, 2015
Computer equipment	$	22,124	$	22,124
Office furniture		4,746		4,746
Less: Accumulated depreciation		(10,809)		(9,582)
Net property and equipment	$	16,061	$	17,288

( us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock )

(End Disclosure - Significant Accounting Policies (Tables))

Disclosure - Notes Payable (Tables)

Disclosure - Notes Payable (Tables) (USD $)

3 Months Ended

( DebtDisclosureAbstract )

Mar. 31, 2016

Long-term Debt

	March 31, 2016		December 31, 2015

Note payable to a private party, interest at 3.0%, interest and principal due December 31, 2017	$	250,000	$	250,000
Note payable to a private party, interest at 3.0%, interest and principal due December 31, 2017		250,000		250,000
		500,000		500,000
Less current maturities of long-term debt		-		-
Long-term debt	$	500,000	$	500,000

Maturities on long-term debt are as follows:

2016	$	-
2017		500,000
	$	500,000

( us-gaap:ScheduleOfDebtTableTextBlock )

(End Disclosure - Notes Payable (Tables))

Disclosure - Provision for Income Taxes (Tables)

Disclosure - Provision for Income Taxes (Tables) (USD $)

3 Months Ended

( IncomeTaxDisclosureAbstract )

Mar. 31, 2016

Income Tax Reconciliation

		For the Three Months Ended March 31,
		2016		2015
Income tax (benefit) computed at
Federal statutory tax rate of 34%	$	(184,634)	$	(290,518)
Change in valuation allowance		232,639		366,053
State taxes (net of federal benefit)		(48,005)		(75,535)
	$	-	$	-

( us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock )

(End Disclosure - Provision for Income Taxes (Tables))

Disclosure - Going Concern and Liquidity Considerations (Details Narrative)

Disclosure - Going Concern and Liquidity Considerations (Details Narrative) (USD $)
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )




Working Capital	$1,092,166
( us-gaap:CashAndCashEquivalentsFairValueDisclosure )
Accumulated Deficit	$18,605,886.
( us-gaap:RetainedEarningsAccumulatedDeficit )

(End Disclosure - Going Concern and Liquidity Considerations (Details Narrative))

Contexts

ID	Period	CIK
From2016-01-01to2016-03-31	2016-01-01 - 2016-03-31	0001405249
AsOf2016-05-16	2016-05-16	0001405249
AsOf2016-03-31	2016-03-31	0001405249
AsOf2015-12-31	2015-12-31	0001405249
From2015-01-01to2015-03-31	2015-01-01 - 2015-03-31	0001405249
AsOf2014-12-31	2014-12-31	0001405249
AsOf2015-03-31	2015-03-31	0001405249

(End Contexts)

Elements

Element		Data Type

AccountingPoliciesAbstract		xbrli:stringItemType	Duration	—

DebtDisclosureAbstract		xbrli:stringItemType	Duration	—

EquityAbstract		xbrli:stringItemType	Duration	—

IncomeTaxDisclosureAbstract		xbrli:stringItemType	Duration	—

OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract		xbrli:stringItemType	Duration	—

OtherLiabilitiesDisclosureAbstract		xbrli:stringItemType	Duration	—

SubsequentEventsAbstract		xbrli:stringItemType	Duration	—

custom:DocumentAndEntityInformationAbstract		xbrli:stringItemType	Duration	—	Yes (Auto)

dei:AmendmentFlag		xbrli:booleanItemType	Duration	—
	If the value is true, then the document is an amendment to previously-filed/accepted document.
dei:CurrentFiscalYearEndDate		xbrli:gMonthDayItemType	Duration	—
	End date of current fiscal year in the format --MM-DD.
dei:DocumentFiscalPeriodFocus		dei:fiscalPeriodItemType	Duration	—
	This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
dei:DocumentFiscalYearFocus		xbrli:gYearItemType	Duration	—
	This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
dei:DocumentPeriodEndDate		xbrli:dateItemType	Duration	—
	The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
dei:DocumentType		dei:submissionTypeItemType	Duration	—
	The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
dei:EntityCentralIndexKey		dei:centralIndexKeyItemType	Duration	—
	A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
dei:EntityCommonStockSharesOutstanding		xbrli:sharesItemType	Instant	—
	Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
dei:EntityCurrentReportingStatus		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
dei:EntityFilerCategory		dei:filerCategoryItemType	Duration	—
	Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
dei:EntityPublicFloat		xbrli:monetaryItemType	Instant	Credit
	State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
dei:EntityRegistrantName		xbrli:normalizedStringItemType	Duration	—
	The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
dei:EntityVoluntaryFilers		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
dei:EntityWellKnownSeasonedIssuer		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
us-gaap:AccountsPayableCurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
us-gaap:AccountsReceivableNet		xbrli:monetaryItemType	Instant	Debit
	For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
us-gaap:AccruedLiabilitiesCurrentAndNoncurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment		xbrli:monetaryItemType	Instant	Credit
	Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
us-gaap:AdditionalPaidInCapital		xbrli:monetaryItemType	Instant	Credit
	Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:Assets		xbrli:monetaryItemType	Instant	Debit
	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
us-gaap:AssetsAbstract		xbrli:stringItemType	Duration	—

us-gaap:AssetsCurrent		xbrli:monetaryItemType	Instant	Debit
	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
us-gaap:AssetsCurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:AssetsNet		xbrli:monetaryItemType	Instant	Debit
	Amount of net assets (liabilities).
us-gaap:AssetsNoncurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:BasisOfAccounting		nonnum:textBlockItemType	Duration	—
	The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
us-gaap:Cash		xbrli:monetaryItemType	Instant	Debit
	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
us-gaap:CashAndCashEquivalentsAtCarryingValue		xbrli:monetaryItemType	Instant	Debit
	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
us-gaap:CashAndCashEquivalentsFairValueDisclosure		xbrli:monetaryItemType	Instant	Debit
	Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
us-gaap:CashAndCashEquivalentsPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
us-gaap:CashPeriodIncreaseDecrease		xbrli:monetaryItemType	Duration	Debit
	Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.
us-gaap:CommonStockParOrStatedValuePerShare		num:perShareItemType	Instant	—
	Face amount or stated value per share of common stock.
us-gaap:CommonStockSharesAuthorized		xbrli:sharesItemType	Instant	—
	The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
us-gaap:CommonStockSharesIssued		xbrli:sharesItemType	Instant	—
	Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
us-gaap:ConcentrationRiskCreditRisk		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for credit risk.
us-gaap:ConsolidationPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
us-gaap:CostOfGoodsSold		xbrli:monetaryItemType	Duration	Debit
	Total costs related to goods produced and sold during the reporting period.
us-gaap:CumulativeEarningsDeficit		xbrli:monetaryItemType	Instant	Credit
	Amount of cumulative earnings (deficits) for relevant time periods.
us-gaap:DebtDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
us-gaap:Deposits		xbrli:monetaryItemType	Instant	Credit
	The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.
us-gaap:Depreciation		xbrli:monetaryItemType	Duration	Debit
	The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
us-gaap:DepreciationAndAmortization		xbrli:monetaryItemType	Duration	Debit
	The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.
us-gaap:EarningsPerShareBasicAndDiluted		num:perShareItemType	Duration	—
	The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
us-gaap:EarningsPerSharePolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
us-gaap:GrossProfit		xbrli:monetaryItemType	Duration	Credit
	Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
us-gaap:IncomeLossFromContinuingOperations		xbrli:monetaryItemType	Duration	Credit
	Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.
us-gaap:IncomeStatementAbstract		xbrli:stringItemType	Duration	—

us-gaap:IncomeTaxDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
us-gaap:IncomeTaxesPaidNet		xbrli:monetaryItemType	Duration	Credit
	The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
us-gaap:IncreaseDecreaseInAccountsPayable		xbrli:monetaryItemType	Duration	Debit
	The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
us-gaap:IncreaseDecreaseInAccountsReceivable		xbrli:monetaryItemType	Duration	Credit
	The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
us-gaap:IncreaseDecreaseInAccruedLiabilities		xbrli:monetaryItemType	Duration	Debit
	The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
us-gaap:IncreaseDecreaseInDeposits		xbrli:monetaryItemType	Duration	Debit
	The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.
us-gaap:IncreaseDecreaseInInventories		xbrli:monetaryItemType	Duration	Credit
	The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
us-gaap:IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract		xbrli:stringItemType	Duration	—

us-gaap:IncreaseDecreaseInPrepaidExpense		xbrli:monetaryItemType	Duration	Credit
	The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
us-gaap:InterestAndDividendIncomeOperating		xbrli:monetaryItemType	Duration	Credit
	Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.
us-gaap:InterestExpense		xbrli:monetaryItemType	Duration	Debit
	Amount of the cost of borrowed funds accounted for as interest expense.
us-gaap:InterestPaid		xbrli:monetaryItemType	Duration	Credit
	The amount of cash paid for interest during the period.
us-gaap:InventoryGross		xbrli:monetaryItemType	Instant	Debit
	Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
us-gaap:InventoryPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.
us-gaap:LiabilitiesAndStockholdersEquity		xbrli:monetaryItemType	Instant	Credit
	Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
us-gaap:LiabilitiesAndStockholdersEquityAbstract		xbrli:stringItemType	Duration	—

us-gaap:LiabilitiesCurrent		xbrli:monetaryItemType	Instant	Credit
	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
us-gaap:LiabilitiesCurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:LiquidityDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substa
us-gaap:LongTermDebtAbstract		xbrli:stringItemType	Duration	—

us-gaap:LongTermDebtNoncurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
us-gaap:NatureOfOperations		nonnum:textBlockItemType	Duration	—
	The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).
us-gaap:NetCashProvidedByUsedInFinancingActivities		xbrli:monetaryItemType	Duration	Debit
	Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
us-gaap:NetCashProvidedByUsedInFinancingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:NetCashProvidedByUsedInInvestingActivities		xbrli:monetaryItemType	Duration	Debit
	Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
us-gaap:NetCashProvidedByUsedInInvestingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:NetCashProvidedByUsedInOperatingActivities		xbrli:monetaryItemType	Duration	—
	Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
us-gaap:NetCashProvidedByUsedInOperatingActivitiesAbstract		xbrli:stringItemType	Duration	—

us-gaap:NetIncomeLoss		xbrli:monetaryItemType	Duration	Credit
	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
us-gaap:NoncashOrPartNoncashAcquisitionNameDomain		nonnum:domainItemType	Duration	—
	The name of the sale of an asset or business acquired through a noncash (or part noncash) transaction.
us-gaap:NotesPayable		xbrli:monetaryItemType	Instant	Credit
	Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
us-gaap:OperatingExpenses		xbrli:monetaryItemType	Duration	Debit
	Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
us-gaap:OperatingExpensesAbstract		xbrli:stringItemType	Duration	—

us-gaap:OtherAssets		xbrli:monetaryItemType	Instant	Debit
	The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.
us-gaap:OtherAssetsAbstract		xbrli:stringItemType	Duration	—

us-gaap:OtherIncomeAndExpensesAbstract		xbrli:stringItemType	Duration	—

us-gaap:OtherLaborRelatedExpenses		xbrli:monetaryItemType	Duration	Debit
	Amount of payroll tax expense, compensation, postemployment and benefit-related expenses not elsewhere specified in the taxonomy (such as health plan, profit sharing, incentives, tuition reimbursement, other fringe benefits and perquisites) incurred in the period.
us-gaap:OtherNoncashExpense		xbrli:monetaryItemType	Duration	Debit
	Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.
us-gaap:OtherNonoperatingIncomeExpense		xbrli:monetaryItemType	Duration	Credit
	The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
us-gaap:PaymentsForPurchaseOfOtherAssets1		xbrli:monetaryItemType	Duration	Credit
	Amount of cash paid to purchase other assets as part of operating activities.
us-gaap:PaymentsOfStockIssuanceCosts		xbrli:monetaryItemType	Duration	Credit
	The cash outflow for cost incurred directly with the issuance of an equity security.
us-gaap:PrepaidExpenseCurrent		xbrli:monetaryItemType	Instant	Debit
	Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
us-gaap:ProceedsFromIssuanceOrSaleOfEquity		xbrli:monetaryItemType	Duration	Debit
	The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
us-gaap:ProceedsFromNotesPayable		xbrli:monetaryItemType	Duration	Debit
	The cash inflow from a borrowing supported by a written promise to pay an obligation.
us-gaap:PropertyPlantAndEquipmentOther		xbrli:monetaryItemType	Instant	Debit
	Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.
us-gaap:PropertyPlantAndEquipmentPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
us-gaap:ReceivablesPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.
us-gaap:ResearchAndDevelopmentExpense		xbrli:monetaryItemType	Duration	Debit
	The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
us-gaap:RetainedEarningsAccumulatedDeficit		xbrli:monetaryItemType	Instant	Credit
	The cumulative amount of the reporting entity's undistributed earnings or deficit.
us-gaap:RevenueRecognitionPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
us-gaap:Revenues		xbrli:monetaryItemType	Duration	Credit
	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
us-gaap:ScheduleOfDebtTableTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
us-gaap:ScheduleOfDerivativeInstrumentsTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.
us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
us-gaap:SellingGeneralAndAdministrativeExpense		xbrli:monetaryItemType	Duration	Debit
	The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.
us-gaap:SignificantAccountingPoliciesTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for all significant accounting policies of the reporting entity.
us-gaap:StatementOfCashFlowsAbstract		xbrli:stringItemType	Duration	—

us-gaap:StatementOfFinancialPositionAbstract		xbrli:stringItemType	Duration	—

us-gaap:StockholdersEquity		xbrli:monetaryItemType	Instant	Credit
	Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
us-gaap:StockholdersEquityAbstract		xbrli:stringItemType	Duration	—

us-gaap:StockholdersEquityNoteDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
us-gaap:SubsequentEventsTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
us-gaap:SupplementalCashFlowInformationAbstract		xbrli:stringItemType	Duration	—

us-gaap:UseOfEstimates		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
us-gaap:WeightedAverageBasicSharesOutstandingProForma		xbrli:sharesItemType	Duration	—
	The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.
Total Elements					127
Total Non-Abstract Elements					99
Total Extension Elements					1
Percent Extended					0%
Percent Extended (excluding abstracts)					0%

(End Elements)